Chuangsheng Group-B (06628): Chuangsheng Pharmaceuticals announced the updated efficacy data of the osemitamab triple therapy for first-line treatment of gastric or gastroesophageal junction adenocarcinoma in stage I/II (Transtar102) at ESMO Asia.

Zhixun Finance APP News, Chansheng Group-B (06628) announced that the company's board of directors is pleased to announce that the combination of osemitamab and nivolumab with CAPOX as first-line treatment for gastric or gastroesophageal junction adenocarcinoma (TranStar102) in Phase I/II clinical trial has shown updated efficacy analysis based on CLDN18.2 and PD-L1 expression. The study results were presented in poster form (abstract number: #299P) at the European Society for Medical Oncology Asia Congress 2025 held in Singapore.